BMS presents positive data from phase 3 True North Trial of Zeposia in UC

This article was originally published here

True North met both primary endpoints, demonstrating highly statistically significant and clinically meaningful results for clinical remission compared to placebo at induction at Week 10 (18.4% versus 6.0%;

The post BMS presents positive data from phase 3 True North Trial of Zeposia in UC appeared first on Pharmaceutical Business review.